Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the
form of cell death that can be regulated by a variety of biomacromolecules, which is …

Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction
pathways that regulate all aspects of life and are frequently altered in disease. Here, we …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi+ MEKi) are FDA-approved to
treat BRAF V600E/K-mutant melanoma. Efficacy of BRAFi+ MEKi associates with cancer cell …

We previously piloted the concept of a Connectivity Map (CMap), whereby genes, drugs,
and disease states are connected by virtue of common gene-expression signatures. Here …

Malignant transformation can result in melanoma cells that resemble different stages of their
embryonic development. Our gene expression analysis of human melanoma cell lines and …

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …

Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer
and are responsible for imparting differential drug responses in cancer patients. Recently …